European Archives - Page 944 of 1057 - European Medical Journal

The Role of Sebelipase Alfa in Treating Lysosomal Acid Lipase Deficiency (LAL-D)

Lysosomal acid lipase deficiency (LAL-D), historically known as Wolman’s disease or cholesteryl ester storage disease, is a severe, underdiagnosed, and…

EMJ

Precision medicine for metastatic breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS…

EMJ

Cut It Out: The Molecular Scissors That Help Prevent Cancers

CANCER can be prevented by ‘molecular scissors’, a protein that is vital for repairing damaged and abnormal DNA, researchers have stated in a discovery…

EMJ

Scientists Map a Path to a Potential HIV-1 Cure

RESEARCHERS have uncovered a potential pathway to curing HIV-1 infection, the predominant strain of the disease worldwide, which could signal hope for…

EMJ Respiratory 3 [ePrint] 2015

Postoperative respiratory failure (RF) is a common problem following all types of major surgery, and which has significant implications for morbidity…

EMJ

Genes Could Be the Answer to Pain Prediction

INFLUENCE of osteoarthritis genetics may be key to pain sensitivity, according to a recent study following 122 patients with knee osteoarthritis. The…

EMJ

Pain Persists in Treated Rheumatoid Arthritis Patients

NEW research has revealed that pain persists in >50% of rheumatoid arthritis (RA) patients treated with methotrexate for 3 months, even in those who…

EMJ

Artificial Intelligence May Help Override Fearful Memories

SCIENTISTS have created a procedure that can remove specific fearful memories from the brain, which could be used as a new therapy for treating…

EMJ

First Patients Enrolled and Dosed in the Pivotal Trial of Phase 3 of the Immunotherapy Tedopi® for Advanced Non-Small Cell Lung Cancer

Paris, February 22nd, 2016, 6:30pm – OSE Pharma SA (ISIN: FR0012127173; Mnémo: OSE), an immunooncology company with a specific immunotherapy…

EMJ

Patient Enrolment Completed in US Phase IIb Study of GrassMATAMPL

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces it has completed…